IP Library › Granted Patent US 12,577,298
Granted Patent B2
US 12,577,298 · App. 17/385,532 · Granted Mar 17, 2026

Anti-IL-5 antibodies

Inventors: Mark Terence Liddament (Haberfield, AU); Anthony Doyle (Macquarie Park, AU); Adam Clarke (Macquarie Park, AU); David Jose Simon Laine (Gladesville, AU); Bridget Ann Cooksey (Macquarie Park, AU)
Assignee: CEPHALON LLC
C07K16/244A61P37/08A61K2039/505C07K2317/21C07K2317/24C07K2317/33C07K2317/54C07K2317/55C07K2317/56C07K2317/565C07K2317/622C07K2317/75C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,577,298
App. No.
17/385,532
Granted
Mar 17, 2026
Kind
B2
Abstract

Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (K D ) of at least about 40 pM as determined by surface plasmon resonance.

Claims (14)

1 . A human antibody molecule that immunospecifically binds to human Interleukin-5 (IL-5), wherein the antibody molecule comprises:

a heavy chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 4, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 8, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 15, and

an IgG4 heavy chain comprising a S228P mutation, a M252Y mutation, a S254T mutation, a T256E mutation, and a deletion of a heavy chain C-terminal lysine residue.

2 . The antibody molecule of claim 1 , wherein the antibody molecule comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 16 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 17.

3 . The antibody molecule of claim 1 , wherein the antibody molecule comprises the IgG4 heavy chain constant region comprising the S228P mutation, the M252Y mutation, the S254T mutation, the T256E mutation, and the deletion of the heavy chain C-terminal lysine residue, and a lambda light chain constant region.

4 . The antibody molecule of claim 3 , wherein the antibody molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 20 and a light chain comprising the amino acid sequence of SEQ ID NO: 19.

5 . A pharmaceutical composition comprising the antibody molecule of claim 1 .

6 . A pharmaceutical composition comprising the antibody molecule of claim 4 .

7 . A nucleic acid molecule encoding the antibody molecule of claim 1 .

8 . A vector comprising the nucleic acid molecule of claim 7 .

9 . An isolated cell transformed to express the antibody molecule of claim 1 .

10 . A nucleic acid molecule encoding the antibody molecule of claim 4 .

11 . A vector comprising the nucleic acid molecule of claim 10 .

12 . An isolated cell transformed to express the antibody molecule of claim 4 .

Assignments (1)
CHANGE OF NAME Recorded Jul 26, 2022
From: CEPHALON, INC.
To: CEPHALON LLC
Reel/Frame 060921/0078 →
Continuity (3)
Continuation 15848090 · Dec 20, 2017
Provisional Application 62438502 · Dec 23, 2016
Related Publication 20210355205A1 · Nov 18, 2021
References Cited (44)
US 6129913A · Ames et al. · 2000 [cited by applicant]
US 11111292B2 · Liddament · 2021 [cited by examiner]
US 20030059429A1 · Ames et al. · 2003 [cited by applicant]
CL 201800499 · 2018 [cited by applicant]
CN 1175263A · 1998 [cited by applicant]
EP 1749840 · 2007 [cited by applicant]
KR 100511544B1 · 2005 [cited by applicant]
WO 8801649A1 · 1988 [cited by applicant]
WO 9201047A1 · 1992 [cited by applicant]
WO 9413804A1 · 1994 [cited by applicant]
WO 9621000 · 1996 [cited by applicant]
WO WO9621000A2 · 1996 [cited by examiner]
WO 9844001A1 · 1998 [cited by applicant]
WO 2003085089 · 2003 [cited by applicant]
WO 2009085462A1 · 2009 [cited by applicant]
WO 2017033121A1 · 2017 [cited by applicant]
WO WO2017070561A1 · 2017 [cited by examiner]
Lazar et al., Mol. Cell. Biol., 8:1247-1252, 1988 (Year: 1988). [cited by examiner]
Burgess et al., J. Cell Biol. 111: 2129-2138, 1990 (Year: 1990). [cited by examiner]
Mateu MG, et. al. Eur J Immunol. Jun. 1992;22(6):1385-9 (Year: 1992). [cited by examiner]
Brown et al., J Immunol. May 1996;156(9):3285-91 (Year: 1996). [cited by examiner]
Greenspan et al., 1999, Nature Biotechnology, 17:936-937 (Year: 1999). [cited by examiner]
Bork. Genome Research, 2000, 10:398-400 (Year: 2000). [cited by examiner]
Skolnick et al., Trends Biotechnol. Jan. 2000;18(1):34-9 (Year: 2000). [cited by examiner]
Vajdos et al., J Mol Biol. Jul. 5, 2002;320(2):415-28 at 416 (Year: 2002). [cited by examiner]
Miosge, Proc Natl Acad Sci U S A. Sep. 15, 2015;112(37):E5189-98 (Year: 2015). [cited by examiner]
Biggest Challenges Encountered When Doing SPR Experiments—Drug Discovery and Development; Dec. 22, 2015; accessed online on Nov. 19, 2024 (Year: 2015). [cited by examiner]
Kulmanov et al., Bioinformatics, 34(4), 2018, 660-668 (Year: 2018). [cited by examiner]
Almagro, J., “Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires” Journal of Molec… [cited by applicant]
Chothia, C. et al., “Canonical structures for the hypervariable regions of immunoglobulins”, J Mol Biol, 1987, 196, 901-917. [cited by applicant]
Gil, et al.; Anti-inflammatory actions of Chemoattractant Receptor-homologous molecule expressed on Th2 by the antagonist MK-7246 in a novel rat model of Alternaria alternata elicited pulmonary inflammation, European Jo… [cited by applicant]
Hart, T. K. et al, “Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys”, Journal of Allergy and Clinical Immunology, 2001, 250-257. [cited by applicant]
Knappik, A. et al., “Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides”, J Mol Biol, 2000, 296, 57-86. [cited by applicant]
Kolkhir P.V., Smolkin Yu.S., Clinical phenotypes of bronchial asthma, Allergology and Immunology in Pediatrics [Allergologya i immunologya v pediatrii], 2010, n° 2 (21), pp. 12 to 17. (English translation attached). [cited by applicant]
Lefranc, M. et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains”, Developmental & Comparative Immunology, 2003, 27, 55-77. [cited by applicant]
Liddament, M. et al., “P155 Higher binding addinity and in-vitro potency of reslizumab for interleukin-5 compared with mepolizumab”, Annals of Allergy, Asthma & Immunology, 2016, abstract. [cited by applicant]
Mukherjee, M. et al.“Anti-1L5 therapy for asthma and beyond”, World Allergy Organization Journal, 2014, 32. [cited by applicant]
Shi et al., De Novo Selection of High-affinity Antibodies from Synthetic Fab libraries Displayed on Phage as pIX Fusion Proteins; J Mol Biol; 2010, 397: 385-396. [cited by applicant]
Strohl W.R., Optimization of Fc-mediated effector functions of monoclonal antibodies, Current Opinion in Biotechnology, 2009, vol. 20, Issue 6, pp. 685-691. [cited by applicant]
Ward el al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Whitelegg, et al: WAM: an improved algorithm for modelling antibodies on the Web, Protein Engineering, vol. 13, No. 12, 2000, 819-824. [cited by applicant]
Wu, et al.; An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and Their Implications for Anti-Body Complementarity; 1970, 132: 211-250. [cited by applicant]
Zhang, Ji et al. “Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5” International Immunology, 1999, 1935-1943. [cited by applicant]
Chuchalin, New prospects in the therapy of bronchial asthma, Pulmonology, 2011, No. 4, 12pp. [cited by applicant]